To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open867.75
High878.9
Low856.55
Prev. Close872
Avg. Traded Price866.14
Volume4,99,490

MARKET DEPTH

info2
Total bid4,812.00
Total ask0.00
OrdersQtyBid
84812872
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

856.5517 hours ago
878.9012 hours ago
arrow

LOWER/UPPER CIRCUITS

692.55
1,038.75
arrow
Natco Pharma Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 15.92%, in the last year to ₹4,784 Cr. Its sector's average revenue growth for the last fiscal year was 10.53%.
noteAnnual Net Profit,rose 35.81% in the last year to ₹1,885.4 Cr. Its sector's average net profit growth for the last fiscal year was 37.23%.
notePrice to Earning Ratio,is 9.13, lower than its sector PE ratio of 41.12.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 10.67%
Net profit growth 5Y CAGR : 16.66%
Natco Pharma Ltd Top mutual funds holding
arrow
Natco Pharma Limited is a vertically integrated and RD focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. It is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.
personal

Grow your wealth with more research recommendations

+91